Fortrea is proud to support our sponsors with a team of over 60 oncologists to committed to navigating the complexities of oncology clinical research and maximizing the impact of their product to the current global therapeutic landscape. With support spanning translational research and early phase development through product launch and post-marketing studies, our team members help guide clinical development planning, establish target product profiles, perform feasibility and risk assessment and provide program-level medical oversight. This collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we've supported. They also have contributed to industry knowledge via articles about their own collaborative and academic work.
Oncology Publications
In 2023, Fortrea oncologists published 14 peer-reviewed articles.
Just a few of the most interesting include:
“Quantifying the Impact of the COVID-19 Pandemic on Clinical Trial Enrollment Screening Rates Over Time in 37 Countries”
COVID-19 made a huge impact on all aspects of human activity, including biomedical research. Fortrea is among the worlds leading CROs and intrinsically involved in the planning, setup, and execution of clinical trials globally. In this article, we analyzed the impact of the pandemic on the trial screening rates in 37 countries.
“Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer”
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting advances in cancer therapeutics in the past decade, and Fortrea has been involved in the execution of clinical trials for many such molecules. In this manuscript, we highlight the growing role of ADCs in non-small cell lung cancer.
“CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond”
Cell and gene therapy, and in particular CAR-T cell therapy, has shown remarkable results in CD19-positive haematological cancers. In this paper, we review the recent progress made in testing CAR-T cell therapy to target B-cell maturation antigen-expressing cells in multiple myeloma.
Check out the full list of our 2023 peer-reviewed oncology publications
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Luca Cantini, Dario Trapani, Lorenzo Guidi, Luca Boscolo Bielo, Roberta Scafetta, Marcin Koziej, Laura Vidal, Kamal S. Saini, Giuseppe Curigliano
Cancer Treatment Reviews, published ~21 December 2023
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
Abhinava K. Mishra, Ashna Gupta, Gunjan Dagar, Dayasagar Das, Abhijit Chakraborty, Shabirul Haque, Chandra Prakash Prasad, Archana Singh, Ajaz A. Bhat, Muzafar A. Macha, Moez Benali, Kamal S. Saini, Rebecca Ann Previs, Deepak Saini, Dwaipayan Saha, Preyangsee Dutta, Aseem Rai Bhatnagar, Mrinalini Darswal, Abhishek Shankar, Mayank Singh.
Vaccines, published 16 Nov 2023
Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate?
Heidi Ko, Rebecca Previs, Kyle Strickland, Brian Caveney, Chiara Chiruzzi, Marcia Eisenberg, Eric Severson, Shakti Ramkissoon, Kamal S. Saini.
Oncology & Therapy, Published 14 November 2023
From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa
Zodwa Dlamini, Thulo Molefi, Richard Khanyile, Mahlori Mkhabele, Botle Damane, Alexandre Kokoua, Meshack Bida, Kamal S. Saini, Nkhensani Chauke-Malinga, Thifhelimbilu Emmanuel Luvhengo and Rodney Hull.
Oncology & Therapy, Published 1 November 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.
Pecci F, Cantini Luca, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R.
Oncologist. 2023 Oct 5
Recent advances in gynecological malignancies: Focus on ASCO 2023
Olga Bodriagova, Rebecca Ann Previs, Lydia Gaba, Abhishek Shankar, Laura Vidal, Kamal S Saini.
Oncology & Therapy, published September 2023
Specific challenges in managing inflammatory breast cancer and inoperable locally advanced breast cancer.
Eniu A, Rachdi H, Offersen BV, Nielsen AWM, Konsoulova A, Ben Ali M, Boussen H.
The European School of Oncology (ESO) (Book Chapter)
Intracellular DNA sensing by neutrophils and amplification of the innate immune response.
Arun K. Mankan, Paulina Czajka-Francuz, Maria Prendes, Sriram Ramanan, Marcin Koziej, Laura Vidal, Kamal S Saini.
Frontiers in Immunology, published June 2023
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.
Paulina Czajka-Francuz, Maria Prendes, Arun Mankan, Ángela Quintana, Sarabjot Pabla, Shakti Ramkissoon, Taylor J. Jensen, Sandra Peiró, Eric A. Severson, Bhagelu R. Achyut, Laura Vidal, Martine Poelman and Kamal S. Saini.
Frontiers in Oncology, published June 2023
RNA sequencing identifies novel NRG1-fusions in solid tumors that lack co-occurring oncogenic drivers.
Eric Severson, B.R. Achyut, Mary Nesline, Sarabjot Pabla, Rebecca A. Previs, Geoffrey Kannan, Anjen Chenn, Shengle Zhang, Roger Klein, Jeffrey Conroy, Mark Sausen, Pratheesh Sathyan, Kamal S. Saini, Aradhana Ghosh, Taylor J. Jensen, Prasanth Reddy, Shakti H. Ramkissoon.
The Journal of Molecular Diagnostics, published May 2023
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study
Cantini Luca, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R.
Journal of National Cancer Institutes, Published April 2023
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.
Idoko Salifu, Navneet Singh, Maria Berraondo, Jordi Remon, Stephanie Salifu, Eric Severson, Angela Quintana, Sandra Peiró, Shakti Ramkissoon, Laura Vidal, Isagani Chico, Kamal S Saini.
Cancer Treatment and Research Communications, published April 2023
Quantifying the Impact of the COVID-19 Pandemic on Clinical Trial Enrollment Screening Rates Over Time in 37 Countries.
Kelsey McDonald, Earl Seltzer, Mary Lu, Stefan Diaz Gaisenband, Cassandra Fletcher, Patrick McLeroth, Kamal S Saini.
Trials, published April 2023
Immune checkpoint inhibitors in breast cancer: a narrative review.
Paulo Nunes Filho, Caroline Albuquerque, Mariana Pilon, Marcio Debiasi
Oncology & Therapy, published March 2023